Lonza aims to speed completion of two commercial production lines for Moderna Inc's trial COVID-19 vaccine so manufacturing could start four to six weeks earlier than planned if the project is successful, the Swiss drugmaker's chairman said on Tuesday.
ZURICH - Lonza aims to speed completion of two commercial production lines for Moderna Inc’s trial COVID-19 vaccine so manufacturing could start four to six weeks earlier than planned if the project is successful, the Swiss drugmaker’s chairman said on Tuesday.
A second commercial line, at Lonza’s site in Visp, Switzerland, had been slated for completion in January or February 2021 but now could be ready in December, he added. “Four to six weeks would be remarkable, if we can gain this time,” Baehny, also Lonza’s interim CEO, said during a video interview. “We know the technology, we feel comfortable with the manufacturing steps. If we can accelerate, let’s do it. This is pandemic speed.”He acknowledged potential bottlenecks, including hiring 60-70 employees to run each production line, availability of contractors and possible shortages of equipment like fermentation gear, could slow things down.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Fauci Says Meetings With Trump On Coronavirus Have 'Dramatically Decreased'Dr. Anthony Fauci, a leading infectious disease expert on the White House’s coronavirus task force, said the frequency of his meetings with President Donald Trump has been “dramatically decreased'
続きを読む »
Fauci Says Meetings With Trump On Coronavirus Have 'Dramatically Decreased'Meanwhile, at least 15 states have seen an uptick in new COVID-19 cases.
続きを読む »
Anthony Fauci on Covid-19 reopenings, vaccines, and moving at 'warp speed'
続きを読む »
133 potential Covid-19 vaccines in the works worldwideThe coronavirus pandemic has brought countries to a standstill. Here's the latest updates on Covid-19 cases, deaths, government responses and more.
続きを読む »
How animals are helping scientists develop COVID-19 vaccinesFerrets, monkeys and other animals are helping scientists answer basic questions about the efficacy of experimental COVID-19 vaccines.
続きを読む »